相关实验视频

Updated: Jun 22, 2025

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Isolation and Purification of Fungal β-Glucan as an Immunotherapy Strategy for Glioblastoma

Published on: June 2, 2023

葡萄糖:对于败血症治疗的治疗替代品

Jesse P M Viana¹, Fernanda F Costa², Tatielle G Dias³

¹Departamento de Biologia Celular Instituto de Ciências Biológicas Programa de Pós Graduação em Ciências Biológicas (Biologia Molecular) Laboratório de Imunologia Aplicada Universidade de Brasília (UnB), Brasília, Brazil.

Journal of immunology research

|June 28, 2024

概括

葡萄糖,特别是β-葡萄糖,在败血症模型中显示有望减少炎症和组织损伤. 这表明葡萄糖可能是管理败血症和改善患者生存率的宝贵工具.

科学领域:

免疫学免疫学免疫学
生物技术是生物技术.
药理学药理学是指药理学的学科.

背景情况:

败血症是一种危及生命的疾病,其特点是宿主对感染的炎症反应失调,导致器官功能障碍.
目前的败血症治疗由于宿主免疫反应的复杂性而面临挑战.
开发新的治疗策略来调节败血症中的免疫反应至关重要.

研究的目的:

审查关于葡萄糖在败血症小鼠模型中的免疫调节作用的科学文献.
分析葡萄糖对炎症反应和败血症生存的影响.
评估葡萄糖作为毒症管理的潜在治疗替代品.

主要方法:

使用系统搜索策略进行了综合性文献审查.
在主要的科学数据库中进行了搜索:PubMed,ScienceDirect,Scopus,Web of Science和Embase.
纳入的研究重点是小鼠的葡萄糖在结和刺穿诱导性败血症模型中的使用.

主要成果:

贝塔葡萄糖是最常被研究的葡萄糖,通常用50毫克/公斤.
在大多数审查的研究中,葡萄糖表明显著降低了炎症反应.
施用葡萄糖导致组织损伤最小化,并增加了动物模型的生存率.

结论:

葡萄糖,特别是β-葡萄糖,在临床前败血症模型中表现出强大的免疫调节作用.
这些发现强调了葡萄糖作为一种有前途的生物技术方法,用于在败血症中调节免疫反应.
葡萄糖具有未来在败血症患者的治疗中临床应用的潜力.

更多相关视频

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies

Published on: April 11, 2012

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model

Published on: November 6, 2020

相关概念视频

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...